Only 5 more trading days until we get the Georgia data from ASCO. I don't expect any news tomorrow...but there are a number of releases that could come out on the 4 trading days next week. It should be a very interesting week.
The four big items that can move the stock price dramatically are great data from the trials; more good financial news from AVID; the release of the Duke/Haynes publication; and partnering news. Once we are into phase III trials they can go very quickly with a SPA that allows for interim looks at ORR and PFS targets that brought about the Avastin approval.
News 
Market Data 
Discover 
